Ignite Creation Date:
2025-12-24 @ 9:15 PM
Ignite Modification Date:
2026-01-02 @ 7:30 PM
Study NCT ID:
NCT00569504
Status:
UNKNOWN
Last Update Posted:
2009-06-12
First Post:
2007-12-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics
Sponsor:
Seoul National Hospital
Organization:
Study Overview
Official Title:
Prevalence of the Metabolic Syndrome in Patients With Schizophrenia Taking Antipsychotics
Status:
UNKNOWN
Status Verified Date:
2009-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the cross-sectional prevalence of the metabolic syndrome in patients with schizophrenia taking antipsychotics.
Detailed Description:
Schizophrenic patients taking any kind of antipsychotics for at least 1 year at the Seoul National Hospital will be participated in this study.
we are planning to enroll approximately 1000 patients with schizophrenia.
For each subject
* abdominal circumference
* body mass index
* lipid profile : TG, HDL-chlo, total chol
* systolic/diastolic blood pressure
* fasting blood glucose will be measured.
we will calculate the rates of patients who meet the criteria for the Metabolic syndrome.
1. Abdominal obesity : absolute criteria
2. 2 or more of followings
1. Triglyceride ≥ 150mg/dL or ongoing treatment
2. HDL-cholesterol \< 40mg/dL (men) HDL-cholesterol \< 50mg/dL (female) or ongoing treatment
3. Hypertension 130mmHg ≥ systolic 85mmHg ≥ diastolic or ongoing treatment
4. FBS ≥ 100mg/dL or previous diagnosis of type II DM
we are planning to enroll approximately 1000 patients with schizophrenia.
For each subject
* abdominal circumference
* body mass index
* lipid profile : TG, HDL-chlo, total chol
* systolic/diastolic blood pressure
* fasting blood glucose will be measured.
we will calculate the rates of patients who meet the criteria for the Metabolic syndrome.
1. Abdominal obesity : absolute criteria
2. 2 or more of followings
1. Triglyceride ≥ 150mg/dL or ongoing treatment
2. HDL-cholesterol \< 40mg/dL (men) HDL-cholesterol \< 50mg/dL (female) or ongoing treatment
3. Hypertension 130mmHg ≥ systolic 85mmHg ≥ diastolic or ongoing treatment
4. FBS ≥ 100mg/dL or previous diagnosis of type II DM
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| PMSPSTA | None | None | View |